DiaMedica Therapeutics (DMAC) EBT (2018 - 2026)
DiaMedica Therapeutics (DMAC) posted quarterly EBT of -$10.0 million for Q1 2026, down 30.31% year-over-year from -$14.4 million in Q1 2025, and down 14.95% quarter-over-quarter from -$8.7 million in Q4 2025.
DiaMedica Therapeutics (DMAC) EBT (2018 - 2026) Analysis & Trends
DiaMedica Therapeutics' EBT history runs 9 years deep, the most recent figure standing at -$10.0 million for Q1 2026.
- In Q1 2026, EBT fell 30.31% year-over-year to -$10.0 million; the TTM figure through Mar 2026 stood at -$35.1 million (down 30.04% YoY), while the FY2025 annual figure was -$32.7 million, down 34.1% from the prior year.
- EBT for Q1 2026 stood at -$10.0 million, down from -$8.7 million in the prior quarter.
- The five-year high for EBT was -$3.1 million in Q3 2022, with the low at -$10.0 million in Q1 2026.
- The 5-year median for EBT is -$5.1 million (2024), against an average of -$5.9 million.
- The sharpest annual moves came in 2022 and 2024: EBT grew 11.36% in 2022, then tumbled 53.55% in 2024.
- DiaMedica Therapeutics' EBT stood at -$3.7 million in 2022, then sank by 37.26% to -$5.1 million in 2023, then sank by 53.55% to -$7.9 million in 2024, then decreased by 10.63% to -$8.7 million in 2025, then dropped by 14.95% to -$10.0 million in 2026.
- Business Quant data shows DMAC's EBT at -$10.0 million in Q1 2026, -$8.7 million in Q4 2025, and -$8.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | DiaMedica Therapeutics | 360.22 Mn | 360.22 Mn | - | -10.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.13 Mn |
| Mar 31, 2026 | -10.04 Mn |
| Dec 31, 2025 | -8.73 Mn |
| Sep 30, 2025 | -8.61 Mn |
| Jun 30, 2025 | -7.69 Mn |
| Mar 31, 2025 | -7.70 Mn |
| Dec 31, 2024 | -7.89 Mn |
| Sep 30, 2024 | -6.27 Mn |
| Jun 30, 2024 | -5.11 Mn |
| Mar 31, 2024 | -5.14 Mn |
| Dec 31, 2023 | -5.14 Mn |
| Sep 30, 2023 | -4.46 Mn |
| Jun 30, 2023 | -4.47 Mn |
| Mar 31, 2023 | -5.27 Mn |
| Dec 31, 2022 | -3.74 Mn |
| Sep 30, 2022 | -3.05 Mn |
| Jun 30, 2022 | -3.35 Mn |
| Mar 31, 2022 | -3.50 Mn |
| Dec 31, 2021 | -3.24 Mn |
| Sep 30, 2021 | -3.44 Mn |